Lustgarten Foundation alleges $22 million funding in 2017 as part of its mission to invest an unprecedented $40 million by the end of 2018. In a bid to advanced pancreatic Cancer research, the foundation is welcoming new researchers to the field.
Andrew Whiteley, the Foundation’s Director of Scientific and Medical Programs said “Part of our overall research strategy is to ensure that we have the very best minds working on solving this problem. Bringing in new thinking from geneticists, biochemists and cell biologists will accelerate our progress. We need to approach this disease from every angle.”
Noteworthy clinical studies utilizing the organoid (three-dimensional cellular models of pancreatic cancer) to tailor treatment options for individual patients are as follows:
- Stand up to Cancer
- Translational Clinical Program
- Research Investigator Program